JUUL E-Cigarette/Vaping Lawsuit

What Is the JUUL Vaping Lawsuit About?

The JUUL e-cigarette lawsuit is a mass tort litigation alleging that JUUL Labs and its major investor Altria Group deliberately designed, marketed, and sold highly addictive nicotine products that targeted minors and caused widespread youth nicotine addiction, lung injuries, and other health problems. The federal cases are consolidated in MDL 2913 in the Northern District of California.

JUUL revolutionized the e-cigarette market when it launched in June 2015 with a device that looked like a USB flash drive and used proprietary pods containing a high-concentration nicotine salt formula — 5% nicotine by weight, roughly equivalent to an entire pack of cigarettes per pod. The device was small enough for teenagers to conceal in a closed hand or pass off as a USB drive, and its smooth nicotine delivery (enabled by the nicotine salt formulation) made it easy for first-time users to inhale without the harsh throat hit associated with traditional cigarettes.

By 2018, JUUL had captured approximately 75% of the U.S. e-cigarette market, and teen vaping rates had skyrocketed. The FDA declared youth e-cigarette use an "epidemic." Thousands of lawsuits followed — from individual families whose children became addicted, from school districts that spent millions addressing the crisis, and from state attorneys general who alleged widespread violations of consumer protection and marketing laws.

JUUL has already agreed to approximately $1.7 billion in settlements with state attorneys general and $255 million with school districts. Individual personal injury claims continue in the MDL. This lawsuit shares thematic similarities with the social media teen mental health lawsuit, which also alleges that corporations designed addictive products that harm minors.

The Teen Vaping Crisis and JUUL's Role

The JUUL lawsuit centers on the company's alleged role in creating a youth nicotine addiction epidemic. The evidence — much of it drawn from JUUL's own internal documents obtained through litigation discovery — paints a picture of a company that was aware its products were being used by minors and took insufficient action to prevent it.

Allegations of Targeting Minors

The lawsuits allege that JUUL employed multiple strategies to attract and addict young users:

• Device design: The JUUL device was designed to resemble a USB flash drive — small, sleek, and easy for students to conceal in a closed hand, pocket, or pencil case. It could be charged in a laptop USB port, further normalizing it in school settings.
• Social media marketing: JUUL's early marketing campaigns used Instagram and other social media platforms popular with teens, featuring young models, parties, and lifestyle imagery. Internal documents revealed that JUUL studied youth trends and social media engagement.
• Flavored pods: JUUL offered flavors such as mango, mint, creme brulee, and fruit medley that were particularly appealing to younger users. Research consistently shows that flavors are a primary reason teens try e-cigarettes. Most flavored pods have since been banned or discontinued.
• High nicotine concentration: JUUL's patented nicotine salt formula delivered 5% nicotine (59 mg/mL) with a smooth throat hit, making it easy for first-time users to inhale without discomfort — lowering the barrier to nicotine initiation.
• Sample distribution: JUUL distributed free samples at parties and events without adequate age verification, according to lawsuit allegations.

JUUL Products Involved in the Lawsuit

The following JUUL products are named or relevant to the litigation. Note that many flavored pods have been discontinued or banned following FDA enforcement actions:

The FDA banned most flavored e-cigarette pods (other than tobacco and menthol) in February 2020. JUUL had voluntarily pulled several flavors from retail in late 2018 in response to public pressure, though they remained available online for a period. In June 2022, the FDA issued a Marketing Denial Order for all JUUL products, though this was later put on hold pending judicial review. JUUL products remain on the U.S. market as of early 2026 while legal and regulatory proceedings continue.

Who Qualifies for the JUUL Lawsuit?

Multiple types of claimants may qualify for the JUUL lawsuit. The strongest claims generally involve minors who became addicted to nicotine or suffered health effects from JUUL products:

Lawsuit Timeline

The JUUL litigation has progressed rapidly. Here are the key milestones:

Settlement Amounts and Verdicts

JUUL has already paid or agreed to pay billions in settlements across different categories of claims. Here is the current landscape:

Individual settlement amounts depend on factors including the severity of addiction, health consequences, the claimant's age at first use, and the duration of JUUL use. For a deeper understanding of how settlements work, read our guide on how settlement funds are distributed.

How to File a JUUL Claim

If you or your child suffered harm from JUUL products, here is the process for pursuing a legal claim:

For a comprehensive overview of the mass tort process, read our guide on how mass tort lawsuits work. You can also learn about why legal representation matters in mass tort cases involving complex product liability claims.

Named Defendants

The JUUL vaping lawsuit names the following defendants:

• JUUL Labs, Inc. — The manufacturer and marketer of the JUUL e-cigarette device and JUUL pods. JUUL Labs is headquartered in Washington, D.C. (relocated from San Francisco). Founded in 2015 as a spin-off from Pax Labs, JUUL rapidly became the dominant e-cigarette brand in the United States. Plaintiffs allege that JUUL designed an intentionally addictive product, marketed it to minors through social media and appealing flavors, and failed to implement adequate age-verification measures.
• Altria Group, Inc. — The parent company of Philip Morris USA (maker of Marlboro cigarettes). Altria invested $12.8 billion in JUUL Labs in December 2018, acquiring a 35% stake. This partnership gave JUUL access to Altria's massive retail distribution network and shelf space. Plaintiffs allege that Altria — with its decades of experience in marketing addictive nicotine products — facilitated JUUL's expansion and contributed to the youth vaping epidemic. Altria has since written down its JUUL investment to near zero due to the litigation and regulatory challenges.

The involvement of Altria — the tobacco industry giant — is a key element of the lawsuit. Plaintiffs argue that the partnership between JUUL and Altria represents a continuation of the tobacco industry's decades-long pattern of targeting young people to create new generations of nicotine-addicted customers. This pattern is well-documented through the related consumer safety litigation in which corporations prioritize profits over the health of vulnerable populations.

Health Effects and Medical Evidence

The JUUL lawsuit alleges that the company's products cause several types of health harm:

Nicotine Addiction

Nicotine is one of the most addictive substances known. The developing adolescent brain is particularly susceptible to nicotine addiction — research shows that teens can develop signs of nicotine dependence within days to weeks of first use, far faster than adults. JUUL's high-concentration nicotine salt formula (5% / 59 mg/mL) delivers nicotine efficiently, and the smooth inhalation experience lowers the barrier to initiation for first-time users. Nicotine exposure during adolescence can also cause lasting harm to brain development, affecting attention, learning, memory, and impulse control.

EVALI (Lung Injury)

In 2019, a nationwide outbreak of EVALI (e-cigarette or vaping product use-associated lung injury) resulted in 2,807 hospitalizations and 68 deaths, according to the CDC's final case count. Important context: The CDC determined that vitamin E acetate — an additive found primarily in illicit THC vaping cartridges, not in commercial nicotine e-cigarettes like JUUL — was the primary cause of most EVALI cases. However, some EVALI cases involved exclusively nicotine products, and the outbreak drew national attention to the potential respiratory risks of vaping. The JUUL lawsuits include claims from individuals who developed lung injury while using JUUL products specifically.

Other Reported Health Effects

• Seizures: The FDA reported that it had received 127 reports of seizures and other neurological events following e-cigarette use between 2010 and 2019. While the causal connection is still being studied, nicotine is known to affect neurological function, particularly in developing brains.
• Respiratory damage: Even outside of EVALI, vaping has been associated with respiratory symptoms including cough, shortness of breath, and chest pain. The long-term pulmonary effects of inhaling aerosolized chemicals from e-cigarettes are not yet fully understood.
• Cardiovascular effects: Nicotine raises blood pressure, increases heart rate, and constricts blood vessels. Heavy nicotine exposure through vaping, particularly at the high concentrations delivered by JUUL, may contribute to cardiovascular risk over time.
• Gateway to combustible cigarettes: Research suggests that adolescents who use e-cigarettes are more likely to subsequently use traditional combustible cigarettes, potentially reversing decades of progress in reducing youth smoking rates.